Natural compound-nanoparticle therapies for breast cancer: A review from 2018-2025
Phytomedicine · 2026-01 · 150 · 157652
DOI: 10.1016/j.phymed.2025.157652 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Phytomedicine, 2026-01. Verfasst von Xiaoyue Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Nanoparticles, Antineoplastic Agents, Phytogenic, Nanoparticle Drug Delivery System. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 275 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Breast cancer (BC) poses significant global challenges due to drug resistance, toxicity, and subtype heterogeneity. Some plant derived natural compounds show multi-target anticancer potential but suffer from poor bioavailability and rapid metabolism. To overcome these intrinsic pharmaceutical limitations, nanotechnology-based delivery strategies have been extensively explored. PURPOSE: This review evaluates the literature from 2018 to 2024 to assess how nanotechnology enables clinical translation of natural compounds by enhancing delivery, overcoming biological barriers, and addressing translational challenges in BC therapy. METHODS: We conducted a comprehensive and critical analysis of the literature concerning the pharmacology of natural compounds with proven anti-BC activity, the design of various nanocarriers (e.g., liposomes, polymeric NPs), targeting approaches (e.g., EPR effect, ligand conjugation), and innovative solutions for tumor microenvironment barriers, biodistribution, and scalability. RESULTS: The analysis of preclinical studies demonstrates that nanoformulations improve natural compound efficacy 2-5-fold. Key advancements include a marked enhancement in solubility and bioavailability, exemplified by an increase in curcumin bioavailability from
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
- Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan province, China.
- School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China; Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
- School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China. Electronic address: kumarg@hku.hk.
- School of Chinese Medicine, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, China. Electronic address: abchen@hku.hk.
Zitieren
APA
Zhang, X., Fei, G., Xiujia, S., Ganesan, K., & Chen, J. (2026). Natural compound-nanoparticle therapies for breast cancer: A review from 2018-2025. Phytomedicine, 150, 157652. https://doi.org/10.1016/j.phymed.2025.157652
Vancouver
Zhang X, Fei G, Xiujia S, Ganesan K, Chen J. Natural compound-nanoparticle therapies for breast cancer: A review from 2018-2025. Phytomedicine. 2026;150:157652. doi:10.1016/j.phymed.2025.157652
BibTeX
@article{Zhang2026,
author = {Zhang, Xiaoyue and Fei, Gao and Xiujia, Sun and Ganesan, Kumar and Chen, Jianping},
title = {Natural compound-nanoparticle therapies for breast cancer: A review from 2018-2025},
journal = {Phytomedicine},
year = {2026},
volume = {150},
pages = {157652},
doi = {10.1016/j.phymed.2025.157652}
}
EUVIMED